Biogen's CEO has pointed to the company's ability to take five drugs into clinical trials so far this year as evidence of its new focus on early-stage R&D. | Biogen's CEO has pointed to the company's ...
Chicago-based Syntax Bio believes it has cracked the code for turning stem cells into pancreatic beta cells in as little as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results